Norinchukin Bank The boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,164 shares of the medical research company's stock after acquiring an additional 1,706 shares during the quarter. Norinchukin Bank The's holdings in Amgen were worth $10,208,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S bought a new position in Amgen in the 4th quarter worth about $7,755,000. Beck Mack & Oliver LLC grew its stake in Amgen by 0.7% in the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock worth $1,205,000 after purchasing an additional 34 shares in the last quarter. Capital International Inc. CA increased its holdings in Amgen by 52.2% during the 4th quarter. Capital International Inc. CA now owns 167,264 shares of the medical research company's stock worth $43,596,000 after purchasing an additional 57,347 shares during the period. Capital Research Global Investors raised its position in Amgen by 20.7% during the 4th quarter. Capital Research Global Investors now owns 4,890,092 shares of the medical research company's stock valued at $1,274,553,000 after purchasing an additional 839,686 shares in the last quarter. Finally, Capital World Investors lifted its holdings in shares of Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the period. Institutional investors own 76.50% of the company's stock.
Amgen Stock Performance
Shares of NASDAQ:AMGN traded down $0.49 on Wednesday, hitting $277.91. 2,679,236 shares of the company were exchanged, compared to its average volume of 2,789,033. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock's 50 day moving average price is $302.25 and its 200 day moving average price is $293.45. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The firm has a market capitalization of $149.42 billion, a P/E ratio of 36.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.
Amgen Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.43%. Amgen's dividend payout ratio (DPR) is presently 126.09%.
Insiders Place Their Bets
In related news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on AMGN shares. Citigroup restated a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Johnson Rice set a $294.00 target price on shares of Amgen in a research report on Wednesday, March 5th. Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Royal Bank of Canada reissued an "outperform" rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Finally, Piper Sandler upped their target price on Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $310.57.
View Our Latest Report on AMGN
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
